News & Media

Newport Laboratories is now part of Boehringer Ingelheim

  • by
  • Jun 12, 2018

DULUTH, Ga. — [June 12, 2018]

Boehringer Ingelheim (BI) is excited to announce that Newport Laboratories, Inc. in Worthington, Minnesota, is officially part of Boehringer Ingelheim’s animal health business unit.

Newport Laboratories enhances the service and product offerings for BI customers. By providing cutting-edge diagnostics like whole genome sequencing, metagenomics, and bioinformatics, Newport Laboratories crafts custom, autogenous vaccines that target the specific viruses or bacteria causing disease in individual livestock operations.

Scrambled eggs with a side of molecular biology

  • by
  • May 05, 2017
Dr. Priya Anbalagan

 (May 5, 2017) – Dr. Priya Anbalagan added molecular biology to the menu during the Academy of Veterinary Consultants 2017 Spring Conference in Irving, Texas, March 30 through April 1. Anbalagan, senior scientist and manager of Diagnostic Services and Technology Development, Newport Laboratories, Inc., presented her research on state-of-the-art diagnostics and bovine respiratory disease to more than 130 veterinarians at a breakfast sponsored by Merial.

Anbalagan demonstrated how Newport is using cutting edge molecular technology to evaluate genetic variations of pathogens.

Randy Shirbroun talks pathology and prevention of diseases

  • by
  • Jun 24, 2016

WORTHINGTON, Minn. – Veterinarian Randy Shirbroun of Newport Laboratories Inc. addressed more than 200 bison producers regarding the pathology and prevention of diseases caused by Mycoplasma bovis. The producers had gathered for the 2016 National Bison Association Summer Conference held in June at Elk River, Minnesota. Shirbroun specializes in ruminant health issues including those seen in the American bison, which became the official U.S. national mammal in May.

Newport Laboratories releases new Mycoplasma bovis Test

  • by
  • Nov 09, 2015

Newport Laboratories, Inc. has developed a new multilocus sequence typing (MLST) technique for Mycoplasma bovis, a significant cause of disease in cattle. The new technology represents a major advancement over the previous diagnostic process and will provide increased resolution and a better assessment of genetic variation that may be associated with antigenic, or strain differences.  This technological advancement utilizing molecular biology is yet another development to come from Newport Laboratories, Inc., a leader in cutting edge diagnostic technology and the manufacturer of autogenous, or custom-made vaccines.  The new MLST technique evaluates 10 variable genes associated with specific Mycoplasma bovis virulence factors, including several of the variable surface proteins (VSPs).

Announcing TS6 Adjuvant Technology for Custom Made SIV Vaccines

  • by
  • Feb 01, 2014
Newport Laboratories is excited to announce that Custom Made SIV Vaccines are now available with TS6 adjuvant technology developed by Merial. This is the same adjuvant that is found in CIRCOVAC® PCV2 vaccine. Newport Laboratories’ Custom Made Vaccines are made from herd-specific pathogens and represent the disease strains circulating in your herd. Our Custom Made Vaccines utilize PINPOINT® diagnostic and production technologies to create a vaccine targeting your specific needs.

Newport Laboratories launches ParaSail

  • by
  • Mar 07, 2012

WORTHINGTON, MN - Newport Laboratories is excited to announce the arrival of ParaSail®, the swine industry's first avirulent live, single-dose vaccine for Haemophilus parasuis.

Available exclusively through veterinarians, ParaSail has been proven to protect against three of the most predominant strains of H. parasuis currently circulating: serotype 4 (found in 25% of cases), serotype 5 (found in 15% of all cases) and serotype 13. Multiple side-by-side comparisons have showed a single dose of the vaccine to be as effective as a two-dose regime. The USDA has approved ParaSail for use as a single-dose product with a 1mL dose size, intramuscular.